Cloud Pharma

//Cloud Pharma

Cloud Pharma & THERAMetrics Target Drug Development for Orphan CNS Diseases

The partnership will initially focus on orphan diseases such as Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). In parallel to these efforts, both companies will pursue sponsored development for additional respiratory indications. […]

October 5th, 2015|

Cloud Pharmaceuticals and Genomeon Announce Marker Discovery and Drug Design Partnership

Cloud Pharmaceuticals and Genomeon Announce Marker Discovery and Drug Design Partnership Relationship to help Cloud Pharmaceuticals identify companion biomarkers effective in targeting cancers and other genetically influenced diseases. […]

August 24th, 2015|

Cloud Pharma CEO to Present This Month at BioTrinity 2015

Ed Addison, CEO of FFVC’s Cloud Pharmaceuticals, will discuss their revolutionary cloud-based approach to drug design and development at Europe’s leading Biopartnering and Investment Conference in London on May 12th.  Addison says “Europe is ahead of the United States in computational drug discovery and design, which is one of the reasons we’re attending BioTrinity.” […]

May 1st, 2015|

Cloud Pharma CEO to Discuss Improving the Accuracy of Drug Discovery at 2015 Bio-IT World Conference & Expo

April 9, 2015 -- Ed Addison, CEO of Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, is being featured as a speaker [...]

April 13th, 2015|

Cloud Pharma, FFVC client, garners SBIR and looks to $20M

A Research Triangle Park company in the drug development space garnered a $150,000 small business grant, but has sights set on $20 million from private [...]

July 30th, 2014|